CPhI and P-MEC India will be held at the Bombay Convention and Exhibition Centre, Mumbai from December 1 to 3, 2015. The three-day event for India’s pharmaceutical industry is expected to attract over 32,000 attendees from across the globe. In 2014, the event witnessed a record participation of 1087 exhibitors from 25 countries and was spread over 55,000 square metres in eight exhibition halls.
At CPhI and P-MEC India, industry professionals will meet first hand with peers from formulations, technology, machinery solutions, contract research, and process developments to packaging – with companies servicing all aspects of the global pharma supply chain.
Technical seminar will run across all three days of the event and will provide a platform to present unique products and offerings to visitors and prospective customers. CPhI and P-MEC India will also have ICSE and BioPh as co-located events.
With the recent CPhI pharma insights report on the Indian pharma economy pointing clearly towards a period of accelerating growth, 2015 is set to be a key year for the industry to meet its new partners and sustain relationships in India. The report entitled ‘CPhI India Pharmaceuticals 2015: Industry explorations’ – included a combined analysis of Indian companies showed an extremely confident domestic outlook in both the near and medium term.
Commenting on CPhI India’s contribution to the transformation of the regional industry, Chris Kilbee, Group Director Pharma, UBM EMEA, said, “CPhI has been a key presence in India for a number of years and the event is an essential cog in internationalising this pharma hub. What’s been most impressive is the ability of companies here to constantly develop themselves through new services and technologies. With the highest number of US FDA approved facilities outside the US, it is unsurprising that India has seen impressive growth in the number of exports. India’s domestic pharma economy is thriving, at the same time as demand for generics is on the rise, and international companies are looking to drive down manufacturing costs. This is an exciting time for the CPhI community to meet at this world-class pharma event.”
